These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11122107)

  • 1. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia.
    Bonifazi F; De Vivo A; Rosti G; Tiribelli M; Russo D; Trabacchi E; Fiacchini M; Montefusco E; Baccarani M
    Br J Haematol; 2000 Nov; 111(2):587-95. PubMed ID: 11122107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group.
    Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A
    Br J Haematol; 1997 Apr; 97(1):76-85. PubMed ID: 9136944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic analysis of chronic myeloid leukemia with Cox model and the Sokal, Hasford score].
    Gan DY; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):662-6. PubMed ID: 16928295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon: comments.
    Pfirrmann M; Hasford J
    Br J Haematol; 2001 Jul; 114(1):241-3. PubMed ID: 11472375
    [No Abstract]   [Full Text] [Related]  

  • 6. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
    Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
    Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in chronic myeloid leukemia. Relationship with interferon and bone marrow transplantation. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Leuk Lymphoma; 1993; 11 Suppl 1():67-71. PubMed ID: 8251920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia.
    Rosti G; Trabacchi E; Bassi S; Bonifazi F; de Vivo A; Martinelli G; Alberti D; Fincato G; Saglio G; Baccarani M;
    Haematologica; 2003 Mar; 88(3):256-9. PubMed ID: 12651262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
    Ashariati A; Ugroseno S
    Acta Med Indones; 2013 Apr; 45(2):107-13. PubMed ID: 23770790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib.
    Chhikara S; Sazawal S; Singh K; Chaubey R; Pati H; Tyagi S; Mahapatra M; Saxena R
    South Asian J Cancer; 2018; 7(4):258-262. PubMed ID: 30430096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Ann Hematol; 1991 Dec; 63(6):307-14. PubMed ID: 1756192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
    Pfirrmann M; Clark RE; Prejzner W; Lauseker M; Baccarani M; Saussele S; Guilhot F; Heibl S; Hehlmann R; Faber E; Turkina A; Ossenkoppele G; Höglund M; Zaritskey A; Griskevicius L; Olsson-Strömberg U; Everaus H; Koskenvesa P; Labar B; Sacha T; Zackova D; Cervantes F; Colita A; Zupan I; Bogdanovic A; Castagnetti F; Guilhot J; Hasford J; Hochhaus A; Hoffmann VS
    Leukemia; 2020 Aug; 34(8):2138-2149. PubMed ID: 32601376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers.
    Sinha SK; Sinha S; Mandal PK; Bhattacharyya NK; Pandey A; Gupta P
    Indian J Pathol Microbiol; 2013; 56(3):216-20. PubMed ID: 24152497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran.
    Payandeh M; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2015; 16(17):7555-9. PubMed ID: 26625761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
    Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
    Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
    Pfirrmann M; Baccarani M; Saussele S; Guilhot J; Cervantes F; Ossenkoppele G; Hoffmann VS; Castagnetti F; Hasford J; Hehlmann R; Simonsson B
    Leukemia; 2016 Jan; 30(1):48-56. PubMed ID: 26416462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia.
    Kloke O; Niederle N; Qiu JY; Wandl U; Moritz T; Nagel-Hiemke M; Hawig I; Opalka B; Seeber S; Becher R
    Br J Haematol; 1993 Mar; 83(3):399-403. PubMed ID: 8485045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.
    Ganta RR; Nasaka S; Linga VG; Gundeti S; Maddali LS; Digumarti RR
    Indian J Med Paediatr Oncol; 2017; 38(3):282-286. PubMed ID: 29200674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.